KVUE:NYSEKenvue Inc. Analysis

Kenvue (KVUE) is trading at $17.97, just above its technical support of $17.87 and below the 20‑day SMA of $18.58, indicating limited upside on the short‑term chart. The RSI sits at 43.8, suggesting neutral momentum, while the MACD remains bearish with the line under the signal and a negative histogram, reinforcing a cautious near‑term outlook. Volume has been decreasing, and volatility over the past 30 days is elevated at roughly 21%, which could amplify price swings. Fundamentally, the company posted a modest 3.2% revenue growth and a solid gross margin of 58% but carries a high debt‑to‑equity ratio of 80.6, raising balance‑sheet concerns. Recent earnings beat (EPS $0.27 vs. $0.22 estimate) and analyst upgrades have lifted sentiment, with the consensus target price around $19.5, implying about a 10% upside. However, the dividend payout ratio exceeds 100%, casting doubt on the sustainability of the 4.57% yield. The forward P/E of 15 is attractive compared to the trailing 23.6, yet the DCF‑derived fair value of $11 suggests the stock is priced well above intrinsic estimates. Overall, KVUE sits in a defensive consumer‑health niche, but the combination of technical weakness, high leverage, and dividend risk tempers enthusiasm.